source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-01 17:38:00
| null |
NEW YORK AND SAN DIEGO, NOV. 01, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCER, TODAY ANNOUNCED THAT ON NOVEMBER 1, 2022, THE COMPENSATION COMMITTEE OF ZENTALIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 350,025 SHARES OF THE COMPANY'S COMMON STOCK TO FOUR NEWLY HIRED EMPLOYEES. THE STOCK OPTIONS WERE GRANTED UNDER THE ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (2022 INDUCEMENT PLAN) AS AN INDUCEMENT MATERIAL TO EACH INDIVIDUAL'S ENTERING INTO EMPLOYMENT WITH ZENTALIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-24 07:00:00
| null |
COMPANIES WILL COLLABORATE ON PHASE 1/2 DOSE ESCALATION STUDY OF ZN-C3, A SELECTIVE WEE1 INHIBITOR, IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN PATIENTS WITH BRAF V600E-MUTATED COLORECTAL CANCER COMPANIES WILL COLLABORATE ON PHASE 1/2 DOSE ESCALATION STUDY OF ZN-C3, A SELECTIVE WEE1 INHIBITOR, IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN PATIENTS WITH BRAF V600E-MUTATED COLORECTAL CANCER
|
ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST ZN-C3 CLINICAL DEVELOPMENT COLLABORATION WITH PFIZER
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-17 07:00:00
| null |
NEW YORK AND SAN DIEGO, OCT. 17, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF MARK LACKNER, PHD, AS CHIEF TRANSLATIONAL OFFICER, HEAD OF BIOMARKER STRATEGY. DR. LACKNER, AN ESTEEMED CANCER BIOLOGIST, JOINS ZENTALIS WITH OVER TWO DECADES OF ONCOLOGY-FOCUSED DRUG DEVELOPMENT EXPERTISE, INCLUDING SIGNIFICANT EXPERIENCE IN BIOMARKER DISCOVERY AND CLINICAL BIOMARKER STRATEGIES.
|
ZENTALIS PHARMACEUTICALS APPOINTS DR. MARK LACKNER AS CHIEF TRANSLATIONAL OFFICER, HEAD OF BIOMARKER STRATEGY
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-03 17:32:00
| null |
NEW YORK AND SAN DIEGO, OCT. 03, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCER, TODAY ANNOUNCED THAT ON OCTOBER 3, 2022, THE COMPENSATION COMMITTEE OF ZENTALIS' BOARD OF DIRECTORS GRANTED THE FOLLOWING EQUITY AWARDS TO DR. CARRIE BROWNSTEIN, WHO JOINED THE COMPANY AS CHIEF MEDICAL OFFICER: NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 300,000 SHARES OF THE COMPANY'S COMMON STOCK WITH TIME-BASED VESTING, NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 100,000 SHARES OF THE COMPANY'S COMMON STOCK WITH PERFORMANCE-BASED VESTING, AND 100,000 RESTRICTED STOCK UNITS (RSUS) WITH TIME-BASED VESTING. THE EQUITY AWARDS WERE GRANTED UNDER THE ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (2022 INDUCEMENT PLAN) AS AN INDUCEMENT MATERIAL TO DR. BROWNSTEIN'S ENTERING INTO EMPLOYMENT WITH ZENTALIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-27 16:01:00
| null |
NEW YORK AND SAN DIEGO, SEPT. 27, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE PROMOTION OF CO-FOUNDER KEVIN BUNKER, PH.D., TO CHIEF SCIENTIFIC OFFICER. IN THIS NEW ROLE, DR. BUNKER WILL FOCUS ON LEADING RESEARCH AND DEVELOPMENT (R&D) IN SAN DIEGO, ADVANCING THE PRECLINICAL PIPELINE AND OPTIMIZING THE COMPANY'S INTEGRATED DISCOVERY ENGINE.
|
ZENTALIS PHARMACEUTICALS PROMOTES CO-FOUNDER KEVIN BUNKER, PH.D. TO CHIEF SCIENTIFIC OFFICER
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-19 07:00:00
| null |
NEW YORK AND SAN DIEGO, SEPT. 19, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF CARRIE BROWNSTEIN, MD, AS CHIEF MEDICAL OFFICER (CMO), EFFECTIVE OCTOBER 3, 2022. DR. BROWNSTEIN, A LEADING ONCOLOGIST AND HEMATOLOGIST BY TRAINING, JOINS ZENTALIS WITH OVER TWO DECADES OF MEDICAL AND BIOPHARMACEUTICAL EXPERIENCE EXECUTING CLINICAL PROGRAM STRATEGIES ACROSS ALL PHASES OF PRODUCT DEVELOPMENT.
|
ZENTALIS PHARMACEUTICALS APPOINTS DR. CARRIE BROWNSTEIN AS CHIEF MEDICAL OFFICER
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-12 07:00:00
| null |
NEW YORK AND SAN DIEGO, SEPT. 12, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF JAN SKVARKA, PHD, MBA TO ITS BOARD OF DIRECTORS. DR. SKVARKA IS AN ACCOMPLISHED BIOPHARMACEUTICAL EXECUTIVE BRINGING OVER THREE DECADES OF EXTENSIVE OPERATIONAL, STRATEGIC AND FINANCIAL EXPERTISE TO ZENTALIS.
|
ZENTALIS PHARMACEUTICALS APPOINTS DR. JAN SKVARKA TO ITS BOARD OF DIRECTORS
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-01 17:00:00
| null |
NEW YORK AND SAN DIEGO, SEPT. 01, 2022 (GLOBE NEWSWIRE) -- ZENTALIS™ PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING CLINICALLY DIFFERENTIATED SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCER, TODAY ANNOUNCED THAT ON SEPTEMBER 1, 2022, THE COMPENSATION COMMITTEE OF ZENTALIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 125,000 SHARES OF ITS COMMON STOCK TO ONE NEW EMPLOYEE. THE STOCK OPTIONS WERE GRANTED UNDER THE ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE “2022 INDUCEMENT PLAN”) AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S ENTERING INTO EMPLOYMENT WITH ZENTALIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-03 07:00:00
| null |
NEW YORK AND SAN DIEGO, AUG. 03, 2022 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THAT KIMBERLY BLACKWELL, MD, CHIEF EXECUTIVE OFFICER OF ZENTALIS, WILL PARTICIPATE IN A PANEL DISCUSSION ENTITLED “BULLSEYE – TARGETED ONCOLOGY – QUANTA OF TARGETS” AT THE WEDBUSH PACGROW HEALTHCARE CONFERENCE ON WEDNESDAY, AUGUST 10, 2022 AT 10:20 A.M. ET.
|
ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN THE WEDBUSH PACGROW HEALTHCARE CONFERENCE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-01 17:10:00
| null |
NEW YORK AND SAN DIEGO, AUG. 01, 2022 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THAT ON AUGUST 1, 2022, THE COMPENSATION COMMITTEE OF ZENTALIS' BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 290,500 SHARES OF ITS COMMON STOCK TO ANDREA PAUL, WHO JOINED ZENTALIS AS ITS GENERAL COUNSEL AND CORPORATE SECRETARY. THE STOCK OPTIONS WERE GRANTED UNDER THE ZENTALIS PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (THE “2022 INDUCEMENT PLAN”) AS AN INDUCEMENT MATERIAL TO MS. PAUL'S ENTERING INTO EMPLOYMENT WITH ZENTALIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZENTALIS PHARMACEUTICALS, INC. ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-27 07:00:00
| null |
NEW YORK AND SAN DIEGO, JUNE 27, 2022 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF ANDREA PAUL, J.D., AS GENERAL COUNSEL AND CORPORATE SECRETARY, EFFECTIVE AUGUST 1, 2022. MS. PAUL BRINGS SEVERAL YEARS OF LEGAL LEADERSHIP EXPERIENCE IN THE HEALTHCARE INDUSTRY TO ZENTALIS.
|
ZENTALIS PHARMACEUTICALS APPOINTS ANDREA PAUL AS GENERAL COUNSEL AND CORPORATE SECRETARY
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-31 07:00:00
| null |
NEW YORK AND SAN DIEGO, MAY 31, 2022 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE PROMOTION OF COFOUNDER CAM GALLAGHER, MBA, TO PRESIDENT. MR. GALLAGHER, WHO PREVIOUSLY SERVED AS AN EXECUTIVE DIRECTOR OF ZENTALIS, WILL REMAIN A MEMBER OF THE BOARD OF DIRECTORS, WHICH HE HAS SERVED ON SINCE THE COMPANY'S FOUNDING. HE WILL REPORT TO CHIEF EXECUTIVE OFFICER DR. KIMBERLY BLACKWELL.
|
ZENTALIS PHARMACEUTICALS PROMOTES COFOUNDER CAM GALLAGHER TO PRESIDENT
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-16 07:28:00
| null |
NEW YORK AND SAN DIEGO, MAY 16, 2022 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING OF 10,330,000 SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $19.38 PER SHARE, FOR TOTAL GROSS PROCEEDS OF APPROXIMATELY $200.2 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY ZENTALIS. ALL OF THE COMMON STOCK IS BEING OFFERED BY ZENTALIS. THE OFFERING IS EXPECTED TO CLOSE ON MAY 18, 2022, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. ZENTALIS INTENDS TO USE THE NET PROCEEDS OF THE OFFERING TO HELP FUND ONGOING AND PLANNED CLINICAL TRIALS, INCLUDING THE CLINICAL DEVELOPMENT OF ZN-C3 AND ZN-D5, AND FOR WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES. ZENTALIS BELIEVES THAT THE NET PROCEEDS FROM THE OFFERING AND ITS EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO THE FIRST QUARTER OF 2025.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-05 07:00:00
| null |
ANNOUNCED INITIAL DATA ON ZN-C3 IN COMBINATION WITH CHEMOTHERAPY IN ADVANCED OVARIAN CANCER AND INTERIM DATA ON ZN-C3 IN UTERINE SEROUS CARCINOMA (USC) AT AACR
|
ZENTALIS PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL UPDATE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-27 07:00:00
| null |
ZENTALIS AND PFIZER PLAN TO JOINTLY ADVANCE THE CLINICAL DEVELOPMENT OF ZN-C3, A SELECTIVE WEE1 INHIBITOR DESIGNED TO INDUCE SYNTHETIC LETHALITY IN CANCER CELLS
|
ZENTALIS PHARMACEUTICALS ANNOUNCES $25 MILLION EQUITY INVESTMENT FROM PFIZER
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-11 16:01:00
| null |
ZN-C3 IN COMBINATION WITH CHEMOTHERAPY DEMONSTRATED STRONG ANTI-TUMOR ACTIVITY IN A HEAVILY PRETREATED POPULATION, WITH AN ORR OF 30.2% ACROSS ALL EVALUABLE CHEMOTHERAPY COHORTS
|
ZENTALIS PHARMACEUTICALS ANNOUNCES OVERVIEW OF CLINICAL AND PRECLINICAL DATA PRESENTED AT AACR
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-08 13:00:00
| null |
ZN-C3 IN COMBINATION WITH CHEMOTHERAPY DEMONSTRATED STRONG ANTI-TUMOR ACTIVITY IN A HEAVILY PRETREATED POPULATION, WITH AN ORR OF 30.2% ACROSS ALL EVALUABLE CHEMOTHERAPY COHORTS
|
ZENTALIS PHARMACEUTICALS ANNOUNCES POSITIVE INITIAL CLINICAL DATA ON ZN-C3, ITS WEE1 INHIBITOR, IN PATIENTS WITH ADVANCED OVARIAN CANCER AT AACR
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-02 07:00:00
| null |
WEBCAST TO BE HELD ON THURSDAY, DECEMBER 16 AT 11:00 A.M. EST WEBCAST TO BE HELD ON THURSDAY, DECEMBER 16 AT 11:00 A.M. EST
|
ZENTALIS PHARMACEUTICALS TO HOST VIRTUAL RESEARCH AND DEVELOPMENT (R&D) DAY ON DECEMBER 16, 2021
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-17 07:00:00
| null |
POTENTIALLY REGISTRATIONAL PHASE 2 TRIAL OF ZN-C3 IN USC IS UNDERWAY, WITH INITIAL ENROLLMENT AND SAFETY UPDATE EXPECTED IN 2H 2022 POTENTIALLY REGISTRATIONAL PHASE 2 TRIAL OF ZN-C3 IN USC IS UNDERWAY, WITH INITIAL ENROLLMENT AND SAFETY UPDATE EXPECTED IN 2H 2022
|
ZENTALIS PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION GRANTED BY THE U.S. FDA TO ZN-C3 FOR THE TREATMENT OF UTERINE SEROUS CARCINOMA
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-13 07:00:00
| null |
INITIAL RESULTS ARE EXPECTED IN 2H 2022 INITIAL RESULTS ARE EXPECTED IN 2H 2022
|
ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1/2 STUDY OF ZN-C3 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH OSTEOSARCOMA
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-01 07:00:00
| null |
NEW YORK AND SAN DIEGO, SEPT. 01, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE PUBLICATION OF THE DISCOVERY OF ZN-C3, THE COMPANY'S HIGHLY POTENT AND SELECTIVE WEE1 INHIBITOR CANDIDATE, IN THE JOURNAL OF MEDICINAL CHEMISTRY.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE JOURNAL OF MEDICINAL CHEMISTRY HIGHLIGHTING THE DISCOVERY OF ITS WEE1 INHIBITOR CANDIDATE ZN-C3
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-12 07:00:00
| null |
REPORTED PROMISING NEW INTERIM DATA ON BOTH ZN-C3 AND ZN-C5, HIGHLIGHTING THEIR POTENTIALLY BEST-IN-CLASS PROFILES
|
ZENTALIS PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL UPDATE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-02 07:30:00
| null |
NEW YORK AND SAN DIEGO, AUG. 02, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 2 TRIAL OF ZN-C3, THE COMPANY'S ORAL WEE1 INHIBITOR PRODUCT CANDIDATE, IN ADULT WOMEN WITH RECURRENT OR PERSISTENT UTERINE SEROUS CARCINOMA (USC). FOLLOWING AN END-OF-PHASE 1 MEETING, THE U.S. FOOD AND DRUG ADMINISTRATION AGREED IN PRINCIPLE THAT ZN-C3 HAS THE POTENTIAL FOR AN ACCELERATED APPROVAL PATHWAY BASED ON THE PHASE 2 GLOBAL STUDY DESIGN IN USC.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN POTENTIALLY REGISTRATIONAL PHASE 2 STUDY OF ZN-C3 IN PATIENTS WITH UTERINE SEROUS CARCINOMA
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-02 07:00:00
| null |
PROCEEDS WILL BE USED TO ADVANCE THE DEVELOPMENT OF THREE ZENTALIS-DISCOVERED ONCOLOGY CLINICAL CANDIDATES AS WELL AS BUSINESS DEVELOPMENT FOR FUTURE PIPELINE ADDITIONS IN CHINA PROCEEDS WILL BE USED TO ADVANCE THE DEVELOPMENT OF THREE ZENTALIS-DISCOVERED ONCOLOGY CLINICAL CANDIDATES AS WELL AS BUSINESS DEVELOPMENT FOR FUTURE PIPELINE ADDITIONS IN CHINA
|
ZENTERA THERAPEUTICS ANNOUNCES CLOSING OF $75 MILLION SERIES B FINANCING
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-01 16:01:00
| null |
NEW YORK AND SAN DIEGO, JULY 01, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE CLOSING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3,565,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $48.50 PER SHARE, WHICH INCLUDES THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE UP TO 465,000 ADDITIONAL SHARES. THE TOTAL GROSS PROCEEDS FOR THE OFFERING ARE APPROXIMATELY $172.9 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY ZENTALIS.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-28 21:09:00
| null |
NEW YORK AND SAN DIEGO, JUNE 28, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3,100,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $48.50 PER SHARE, FOR TOTAL GROSS PROCEEDS OF APPROXIMATELY $150.4 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY ZENTALIS. ALL OF THE COMMON STOCK IS BEING OFFERED BY ZENTALIS. THE OFFERING IS EXPECTED TO CLOSE ON JULY 1, 2021, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, ZENTALIS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 465,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON STOCK
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-28 16:18:00
| null |
NEW YORK AND SAN DIEGO, JUNE 28, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE COMMENCEMENT OF A PROPOSED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK. ALL SHARES OF COMMON STOCK TO BE SOLD IN THE PROPOSED OFFERING WILL BE SOLD BY ZENTALIS. ZENTALIS ALSO EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $22.5 MILLION SHARES OF COMMON STOCK.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-28 07:00:00
| null |
NEW YORK AND SAN DIEGO, MAY 28, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THAT ANTHONY SUN, MD, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZENTALIS AND MELISSA EPPERLY, MBA, CHIEF FINANCIAL OFFICER OF ZENTALIS, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 4, 2021 AT 2:30 P.M. ET.
|
ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-17 07:00:00
| null |
REPORTED ROBUST INITIAL RESULTS FROM THE PHASE 1 MONOTHERAPY DOSE ESCALATION TRIAL OF ITS WEE1 INHIBITOR, ZN-C3, DEMONSTRATING SINGLE-AGENT ACTIVITY AND EXCEPTIONAL RESPONSES IN HEAVILY PRE-TREATED PATIENTS
|
ZENTALIS PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL UPDATE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-12 07:00:00
| null |
ZN-C3 IS CURRENTLY BEING EVALUATED IN PATIENTS WITH ADVANCED SOLID TUMORS AND OVARIAN CANCER ZN-C3 IS CURRENTLY BEING EVALUATED IN PATIENTS WITH ADVANCED SOLID TUMORS AND OVARIAN CANCER
|
ZENTALIS PHARMACEUTICALS ENTERS INTO CLINICAL COLLABORATION AND SUPPLY AGREEMENT WITH GLAXOSMITHKLINE TO EVALUATE ITS ORAL WEE1 INHIBITOR, ZN-C3, IN COMBINATION WITH NIRAPARIB, A PARP INHIBITOR
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-10 13:30:00
| null |
ZN-C3 DEMONSTRATED SINGLE AGENT ACTIVITY, GENERATING EXCEPTIONAL RESPONSES IN A RANGE OF HEAVILY PRE-TREATED SOLID TUMORS
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PROMISING INITIAL DATA PRESENTED IN A LATE-BREAKING SESSION AT AACR ON ZN-C3, ITS WEE1 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-25 07:00:00
| null |
INITIATED MULTIPLE EARLY-STAGE CLINICAL TRIALS EVALUATING ITS ORAL SERD, ZN-C5, WEE1 INHIBITOR, ZN-C3 AND BCL-2 INHIBITOR, ZN-D5
|
ZENTALIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL UPDATE
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 16:30:00
| null |
ADDITIONAL PRECLINICAL DATA ON ZN-C3 AND THE COMPANY'S EGFR INHIBITOR, ZN-E4, WILL BE PRESENTED AS POSTER PRESENTATIONS ADDITIONAL PRECLINICAL DATA ON ZN-C3 AND THE COMPANY'S EGFR INHIBITOR, ZN-E4, WILL BE PRESENTED AS POSTER PRESENTATIONS
|
ZENTALIS PHARMACEUTICALS ANNOUNCES LATE-BREAKER ORAL PRESENTATION ON WEE1 INHIBITOR, ZN-C3, AT THE AACR ANNUAL MEETING 2021
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-10 07:00:00
| null |
NEW YORK & SAN DIEGO, FEB. 10, 2021 (GLOBE NEWSWIRE) -- ZENTALIS PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING SMALL MOLECULE THERAPEUTICS TARGETING FUNDAMENTAL BIOLOGICAL PATHWAYS OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF ENOCH KARIUKI, PHARMD, TO ITS BOARD OF DIRECTORS. DR. KARIUKI IS A HIGHLY ACCOMPLISHED FINANCE EXECUTIVE, BRINGING OVER A DECADE OF DEEP EXPERTISE IN LIFE SCIENCES INVESTMENT BANKING, STRATEGIC ADVISING AND BUSINESS DEVELOPMENT TO ZENTALIS.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF DR. ENOCH KARIUKI TO ITS BOARD OF DIRECTORS
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-13 11:30:00
| null |
ZENTALIS PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL UPDATE.ZENTALIS PHARMA - EXPECT EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES, PROCEEDS FROM OFFERING, TO FUND OPERATING EXPENSES, CAPEX NEEDS INTO 2023.ZENTALIS PHARMACEUTICALS INC - QTRLY NET LOSS PER COMMON SHARE $0.78.
|
ZENTALIS PHARMACEUTICALS POSTS QTRLY NET LOSS PER COMMON SHARE $0.78
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-27 18:30:00
| null |
ZENTALIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.75 MILLION COMMON SHARES.SAYS OFFERING 3.75 MILLION COMMON SHARES.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-27 09:30:00
| null |
ZENTALIS PHARMACEUTICALS INC -.ZENTALIS PHARMACEUTICALS - UNDER TERMS, CO IS RESPONSIBLE FOR CONDUCTING STUDY WITH LILLY PROVIDING ALL REQUIRED DOSES OF ABEMACICLIB.ZENTALIS PHARMACEUTICALS INC - MAINTAINS FULL OWNERSHIP OF ZN-C5.ZENTALIS PHARMACEUTICALS - CLINICAL COLLABORATION AGREEMENT WITH ELI LILLY IN WHICH CO WILL EVALUATE COMBINATION OF ZN-C5 AND VERZENIO.
|
ZENTALIS PHARMACEUTICALS INC ANNOUNCES CLINICAL COLLABORATION AGREEMENT WITH ELI LILLY
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-29 12:30:00
| null |
TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED REPORTS 7.4% PASSIVE STAKE IN ZENTALIS PHARMACEUTICALS INC AS OF MAY 29 - SEC FILING.
|
TYBOURNE CAPITAL MANAGEMENT LIMITED REPORTS 7.4% PASSIVE STAKE IN ZENTALIS PHARMACEUTICALS INC AS OF MAY 29 - SEC FILING
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-20 09:30:00
| null |
ZENTALIS PHARMACEUTICALS ANNOUNCES $20 MILLION SERIES A FINANCING TO ESTABLISH A CHINESE JOINT VENTURE, ZENTERA THERAPEUTICS.ZENTALIS PHARMACEUTICALS - PROCEEDS FROM FINANCING WILL BE USED TO DEVELOP, COMMERCIALIZE 3 CANCER THERAPIES DISCOVERED BY CO.ZENTALIS PHARMACEUTICALS INC - PROCEEDS FROM SERIES A FINANCING WILL BE USED TO DEVELOP AND COMMERCIALIZE POTENTIAL FUTURE CANDIDATES IN CHINA.ZENTALIS PHARMACEUTICALS INC - ANTHONY SUN, MD, CEO OF ZENTALIS, WILL SERVE AS CEO OF ZENTERA.
|
ZENTALIS PHARMA ANNOUNCES $20 MLN SERIES A FINANCING TO ESTABLISH A CHINESE JOINT VENTURE, ZENTERA THERAPEUTICS
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-30 10:30:00
| null |
ZENTALIS PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR ZN-D5 FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.
|
ZENTALIS PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-03 14:30:00
| null |
ZENTALIS PHARMACEUTICALS LLC SHARES OPEN AT $25.20 IN DEBUT ON THE NASDAQ VERSUS IPO PRICE OF $18.00/SHARE.
|
ZENTALIS PHARMACEUTICALS SHARES OPEN 40% ABOVE IPO PRICE IN DEBUT
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-02 23:30:00
| null |
ZENTALIS PHARMACEUTICALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 9.18 MILLION COMMON SHARES PRICED AT $18.00PER SHARE.COMMON STOCK EXPECTED TO BEGIN TRADING ON NASDAQ GLOBAL MARKET ON APRIL 3, UNDER TICKER SYMBOL "ZNTL".
|
ZENTALIS PHARMACEUTICALS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
|
ZNTL
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-09 07:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 9, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A LEADING INNOVATOR IN VETERINARY MEDICINE OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, ANNOUNCED TODAY THE LAUNCH OF THE REVOLUTIONARY TRUVIEWTM DIGITAL MICROSCOPY PLATFORM, FEATURING THE PROPRIETARY TRUPREPTM SYSTEM THAT AUTOMATICALLY PREPARES SLIDES, ALONG WITH LIQUIVIEWTM LIQUID LENS TECHNOLOGY THAT PROVIDES BEST-IN-CLASS IMAGES. MICROSCOPIC EXAMINATION OF BLOOD AND CYTOLOGY FLUIDS IS THE STANDARD OF CARE IN THE VETERINARY INDUSTRY AND IS UTILIZED BY ESSENTIALLY EVERY VETERINARY PRACTICE.
|
ZOMEDICA LAUNCHES REVOLUTIONARY TRUVIEW(TM) DIGITAL MICROSCOPE WITH ADVANCED OPTICS, AUTOMATED SLIDE PREPARATION, AND TELEPATHOLOGY SERVICES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-11 16:25:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MAY 11, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2023. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA ANNOUNCES RECORD FIRST QUARTER 2023 FINANCIAL RESULTS: REVENUE UP 45% TO $5.5 MILLION; STRONG 70% GROSS MARGIN & $147.5 MILLION IN LIQUIDITY
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-08 06:30:00
| null |
ANN ARBOR, ML / ACCESSWIRE / MAY 8, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ('ZOMEDICA' OR THE 'COMPANY'), TODAY ANNOUNCED IT HAS EXERCISED ITS OPTION TO MOVE FORWARD WITH THE ACQUISITION OF STRUCTURED MONITORING PRODUCTS, INC. (SMP), THE MAKERS OF VETGUARDIAN™ ZERO-TOUCH VITAL SIGNS REMOTE MONITORING SYSTEM, AT A PREVIOUSLY NEGOTIATED PURCHASE PRICE. EXERCISING THIS OPTION BEGAN A PERIOD WHERE THE COMPANIES HAVE AGREED TO WORK TOGETHER TO COMPLETE DUE DILIGENCE AND NEGOTIATE A DEFINITIVE ACQUISITION AGREEMENT.
|
ZOMEDICA EXERCISES OPTION TO ACQUIRE STRUCTURED MONITORING PRODUCTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-31 09:00:00
| null |
ORLANDO, FL / ACCESSWIRE / MARCH 31, 2023 / REDCHIP COMPANIES WILL AIR A NEW INTERVIEW WITH ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ON THE REDCHIP MONEY REPORT® ON BLOOMBERG TV, THIS SATURDAY, APRIL 1, AT 7 P.M. EASTERN TIME (ET).
|
ZOMEDICA CORP. INTERVIEW TO AIR ON BLOOMBERG U.S. ON THE REDCHIP MONEY REPORT(R)
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-17 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MARCH 17, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, ANNOUNCED THAT IT HAS APPOINTED PETER L. DONATO AS ITS CHIEF FINANCIAL OFFICER, EFFECTIVE MARCH 16, 2023.
|
ZOMEDICA APPOINTS NEW CHIEF FINANCIAL OFFICER
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-15 16:45:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MARCH 15, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA CORPORATION REPORTS 2022 RESULTS: $18.9 MILLION REVENUE; 72% GROSS MARGIN & $156 MILLION IN LIQUIDITY - REVENUE UP 361% FROM 2021 THROUGH COMBINATION OF ACQUISITIONS AND ORGANIC GROWTH
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-09 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / FEBRUARY 9, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY REPORTED ITS PRELIMINARY UNAUDITED RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED 2022. PRELIMINARY (UNAUDITED) FOURTH QUARTER AND FULL YEAR 2022 RESULTS: REVENUE FOR THE FOURTH QUARTER OF 2022 IS EXPECTED TO BE APPROXIMATELY $6.0-$6.2 MILLION, AN INCREASE OF 46-51% COMPARED TO THE SAME PRIOR YEAR PERIOD, PRIMARILY DRIVEN BY AN INCREASE IN PULSEVET® SALES AND THE INCLUSION OF THE RECENTLY ACQUIRED ASSISI® PRODUCTS.
|
ZOMEDICA REPORTS PRELIMINARY RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2022
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-08 16:15:00
| null |
ORLANDO, FL / ACCESSWIRE / FEBRUARY 8, 2023 / REDCHIP COMPANIES WILL AIR A NEW INTERVIEW WITH ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY") ON THE REDCHIP MONEY REPORT® ON BLOOMBERG TV, THIS SATURDAY, FEBRUARY 11, AT 7 P.M. EASTERN TIME (ET).
|
ZOMEDICA INTERVIEW TO AIR ON BLOOMBERG U.S. ON THE REDCHIP MONEY REPORT(R)
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-24 06:00:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JANUARY 24, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY") ANNOUNCED TODAY THAT THE COMPANY WILL BE PARTICIPATING IN THE LYTHAM PARTNERS INVESTOR SELECT CONFERENCE TAKING PLACE VIRTUALLY ON JANUARY 31, 2023. COMPANY WEBCAST THE COMPANY'S WEBCAST PRESENTATION WILL BE AVAILABLE FOR VIEWING AT 9:00AM ET ON TUESDAY, JANUARY 31, 2023, AT HTTPS://WSW.COM/WEBCAST/LYTHAM7/ZOM/1898244, AND SUBSEQUENTLY ON THE COMPANY'S WEBSITE AT WWW.ZOMEDICA.COM.
|
ZOMEDICA TO PARTICIPATE IN THE LYTHAM PARTNERS INVESTOR SELECT CONFERENCE
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-18 06:00:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JANUARY 18, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED A STRATEGIC RESTRUCTURING OF ITS EXISTING DEVELOPMENT AND COMMERCIALIZATION AGREEMENTS WITH QORVO BIOTECHNOLOGIES ("QORVO") FOR THE COMPANY'S TRUFORMA® LINE OF PRODUCTS. "THIS IS AN EXCITING MILESTONE FOR ZOMEDICA AS IT PROVIDES US CONTROL OVER THE DEVELOPMENT AND MANUFACTURING OF OUR TRUFORMA PRODUCTS.
|
ZOMEDICA TO TAKE CONTROL OF NEW ASSAY DEVELOPMENT AND MANUFACTURING OF TRUFORMA PRODUCT LINE THROUGH LONG-TERM LICENSING AGREEMENT WITH QORVO BIOTECHNOLOGIES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-17 06:00:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JANUARY 17, 2023 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT IN COOPERATION WITH STRUCTURED MONITORING PRODUCTS, INC. (SMP), IT WILL BEGIN COMMERCIALIZING THE REVOLUTIONARY VETGUARDIAN® ZERO-TOUCH VITAL SIGNS REMOTE MONITORING SYSTEM FOR VETERINARY PROFESSIONALS. THE VETGUARDIAN SYSTEM IS THE FIRST AND ONLY SYSTEM FOR THE COMPANION ANIMAL MARKET THAT ENABLES CONTACT-FREE, CONTINUOUS MONITORING OF PETS' VITAL SIGNS, INCLUDING TEMPERATURE, PULSE, AND RESPIRATION ("TPR").
|
ZOMEDICA EXPANDS RELATIONSHIP WITH STRUCTURED MEDICAL PRODUCTS AND BEGINS COMMERCIALIZING VETGUARDIAN WIRELESS MONITORS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-15 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / DECEMBER 15, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, ANNOUNCES AN UPDATE INTERVIEW WITH THE WALL STREET ANALYZER, AND LARRY HEATON, ZOMEDICA'S CHIEF EXECUTIVE OFFICER. JUAN COSTELLO, SENIOR ANALYST WITH THE WALL STREET ANALYZER, AND LARRY HEATON, THE CHIEF EXECUTIVE OFFICER FOR ZOMEDICA ADDRESSED VARIOUS TOPICS RELATED TO THE COMPANY.
|
ZOMEDICA CEO INTERVIEW WITH WALL STREET ANALYZER UPDATES COMPANY PROGRESS AND PLANS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-14 16:20:00
| null |
ANN ARBOR, MI / ACCESSWIRE / NOVEMBER 14, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY", A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2022. AMOUNTS ARE PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS: $4.78 MILLION REVENUE; 75% GROSS MARGIN & $158.49 MILLION IN CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE SECURITIES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-13 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / SEPTEMBER 13, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING NOVEL DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THE COMMERCIAL LAUNCH OF ITS NEWEST ASSAY - FREE T4 (FT4) - FOR THE TRUFORMA IN-CLINIC BIOSENSOR TESTING PLATFORM. "THE PROPRIETARY POINT-OF-CARE TRUFORMA FREE T4 ASSAY BRINGS A VALUABLE DIAGNOSTIC TOOL INTO THE VETERINARY CLINIC FOR THE FIRST TIME," SAID LARRY HEATON, ZOMEDICA'S CHIEF EXECUTIVE OFFICER.
|
ZOMEDICA ANNOUNCES LAUNCH OF FREE T4 ASSAY FOR TRUFORMA(R) DIAGNOSTIC PLATFORM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-06 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / SEPTEMBER 6, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR EQUINE AND COMPANION ANIMALS, IS PLEASED TO ANNOUNCE THAT THE PULSEVET SYSTEM HAS BEEN NAMED THE OFFICIAL SHOCK WAVE THERAPY OF THE NATIONAL CUTTING HORSE ASSOCIATION. "THE NCHA IS DELIGHTED FOR THIS LONGSTANDING PARTNERSHIP WITH PULSEVET TO CONTINUE," SAID JAY WINBORN, NCHA EXECUTIVE DIRECTOR.
|
ZOMEDICA ANNOUNCES DESIGNATION OF PULSEVET® SYSTEM AS THE OFFICIAL SHOCK WAVE THERAPY OF THE NATIONAL CUTTING HORSE ASSOCIATION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-23 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / AUGUST 23, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ('ZOMEDICA' OR THE 'COMPANY'), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT PAMELA NICHOLS, DVM HAS BEEN APPOINTED TO ITS BOARD OF DIRECTORS AND IS JOINING THE AUDIT AND GOVERNANCE COMMITTEES. DR. NICHOLS IS THE FOUNDER OF SIX SUCCESSFUL VETERINARY HOSPITALS AND DOG BOARDING/DAYCARE FACILITIES.
|
ZOMEDICA APPOINTS DR. PAMELA NICHOLS, DVM TO BOARD OF DIRECTORS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-15 17:20:00
| null |
ANN ARBOR, MI / ACCESSWIRE / AUGUST 15, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY, A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2022. AMOUNTS ARE PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS OF $4.2 MILLION OF REVENUE; 71% GROSS MARGIN & $186.8 MILLION IN CASH; REVENUE UP 51% FROM 2021 COMBINED REVENUES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-18 06:15:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JULY 18, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT IT HAD ACQUIRED SUBSTANTIALLY ALL THE ASSETS OF ASSISI ANIMAL HEALTH LLC ("ASSISI"). ASSISI HAS CREATED AN INNOVATIVE LINE OF TARGETED PULSED ELECTROMAGNETIC FIELD (TPEMF™) DEVICES FOR COMPANION ANIMALS THAT PROVIDE A SAFE, DRUG-FREE ALTERNATIVE FOR TREATING PAIN, INFLAMMATION, ANXIETY, OR BEHAVIORAL DISORDERS.
|
ZOMEDICA ACQUIRES ASSETS OF LEADING TPEM(TM) COMPANY ASSISI ANIMAL HEALTH
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-07 16:15:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JULY 7, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, IS EXPANDING ITS MANUFACTURING AND DISTRIBUTION FACILITY IN ROSWELL GEORGIA, WHICH WILL SIGNIFICANTLY INCREASE CAPACITY FOR PRODUCTION AND DISTRIBUTION OF ITS PRODUCTS. "OUR PULSEVET AND TRUFORMA PRODUCT SALES ARE GROWING, AND WE ARE ADDING REVO2 AND VETGUARDIAN PRODUCTS TO THE MIX.
|
ZOMEDICA ANNOUNCES NEW GLOBAL MANUFACTURING & DISTRIBUTION CENTER
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-06 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JULY 6, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ('ZOMEDICA' OR THE 'COMPANY'), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT THE ACQUISITION OF THE ASSETS OF REVO SQUARED LLC ('REVO') WAS RECENTLY COMPLETED. REVO'S INNOVATIVE MICROVIEW DIGITAL CYTOLOGY PLATFORM WILL PROVIDE VETERINARIANS WITH BEST-IN-CLASS IMAGE QUALITY WHILE PROVIDING THE FIRST IN-CLINIC AUTOMATED SLIDE PREPARATION SYSTEM.
|
ZOMEDICA FINALIZES ACQUISITION OF VETERINARY IMAGING COMPANY REVO SQUARED
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 28, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR EQUINE AND COMPANION ANIMALS, IS HONORED TO ANNOUNCE THAT THE UNITED STATES EQUESTRIAN FEDERATION (USEF) HAS NAMED PULSEVET AS THE OFFICIAL SHOCK WAVE THERAPY SUPPLIER OF US EQUESTRIAN TEAM VETERINARIANS. "THE USEF IS PLEASED TO PARTNER WITH A COMPANY THAT SUPPORTS OUR EFFORTS TO IMPROVE THE WELFARE OF OUR HORSES," SAID BILL MORONEY, CEO OF US EQUESTRIAN.
|
ZOMEDICA ANNOUNCES DESIGNATION OF PULSEVET(R) SYSTEM AS THE OFFICIAL SHOCK WAVE THERAPY SUPPLIER OF THE UNITED STATES EQUESTRIAN TEAM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-21 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 21, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, ANNOUNCED TODAY THAT GREG BLAIR, ZOMEDICA'S VICE PRESIDENT OF BUSINESS DEVELOPMENT & STRATEGIC PLANNING, WILL PARTICIPATE IN A PANEL DISCUSSION AND WILL PROVIDE A DEEP DIVE INTO HOW ZOMEDICA'S PRODUCTS AND LATEST TECHNOLOGIES ARE SUPPORTING VETERINARIANS IN THE POST-COVID WORLD AT ANIMAL HEALTH, NUTRITION & TECHNOLOGY INNOVATION USA SCHEDULED IN BOSTON, JUNE 21-23, 2022. THE FORUM PROVIDES A RARE OPPORTUNITY TO SEE THE NEWEST TECHNOLOGIES FROM THE ANIMAL HEALTH SPACE WHILE NETWORKING WITH SOME OF THE INDUSTRY'S SENIOR EXECUTIVES.
|
ZOMEDICA TO PARTICIPATE IN PANEL DISCUSSION AT ANIMAL HEALTH INVESTMENT FORUM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-15 06:15:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 15, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED IT HAS SIGNED A DEFINITIVE AGREEMENT TO ACQUIRE SUBSTANTIALLY ALL OF THE ASSETS OF REVO SQUARED LLC ("REVO"). REVO'S INNOVATIVE MICROVIEW DIGITAL CYTOLOGY PLATFORM WILL PROVIDE VETERINARIANS WITH BEST-IN-CLASS IMAGE QUALITY WHILE PROVIDING THE FIRST IN-CLINIC AUTOMATED SLIDE PREPARATION SYSTEM.
|
ZOMEDICA TO ACQUIRE ASSETS OF INNOVATIVE VETERINARY IMAGING COMPANY REVO SQUARED
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-13 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 13, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, HAS INITIATED A STUDY TO EVALUATE SHOCK WAVE THERAPY AS A TREATMENT FOR EXERCISED INDUCED PULMONARY HEMORRHAGE (EIPH). EIPH OR "BLEEDING" OCCURS IN HORSES WHEN PULMONARY BLOOD VESSELS IN THE LUNGS RUPTURE AFTER INTENSE EXERCISE.
|
ZOMEDICA TO INVESTIGATE SHOCK WAVE THERAPY OF EXERCISED INDUCED PULMONARY HEMORRHAGE IN HORSES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-02 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JUNE 2, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, ANNOUNCED THAT IT HAS APPOINTED KAREN DEHAAN-FULLERTON AS ITS GENERAL COUNSEL AND CORPORATE SECRETARY. SHE JOINED THE ZOMEDICA TEAM ON MAY 31, 2022.
|
KAREN DEHAAN-FULLERTON JOINS ZOMEDICA AS GENERAL COUNSEL AND CORPORATE SECRETARY
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-19 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MAY 19, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT IT HAS PURCHASED A $1.0 MILLION CONVERTIBLE NOTE FROM STRUCTURED MONITORING PRODUCTS, INC. (SMP), MAKERS OF THE VETGUARDIANTM WIRELESS REMOTE PET MONITORING PLATFORM, AND IN CONNECTION THEREWITH HAS ACQUIRED THE OPTION TO ACT AS A SALES AGENT FOR SMP'S PLATFORM. UNDER THE TERMS OF THE AGREEMENT, ZOMEDICA WILL ALSO HAVE THE OPTION TO ACQUIRE THE VETGUARDIAN PRODUCT LINE FOR USE IN ANIMAL HEALTH.
|
ZOMEDICA ENTERS INTO STRATEGIC INVESTMENT AND POTENTIAL COLLABORATION FOR VETGUARDIAN MONITORING PRODUCT LINE
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-18 08:00:00
| null |
NEW YORK, NY / ACCESSWIRE / MAY 18, 2022 / TRADERS NEWS SOURCE, A LEADING INDEPENDENT EQUITY RESEARCH AND CORPORATE ACCESS FIRM FOCUSED ON SMALL AND MID CAP PUBLICLY TRADED COMPANIES RECENTLY ISSUED A NEW C-LEVEL INTERVIEW FEATURING LARRY HEATON, CEO OF ZOMEDICA CORP. MARK ROBERTS, SENIOR EDITOR AT TRADERSNEWSSOURCE.COM RECENTLY CONDUCTED THE INTERVIEW WITH LARRY HEATON, CEO OF ZOMEDICA CORP. (NYSE AMERICAN:ZOM). MARK DILIGENTLY FOCUSED ON QUESTIONS HE THOUGHT WOULD BE ON THE MINDS OF MOST CURRENT AND FUTURE SHAREHOLDERS.
|
TRADERS NEWS SOURCE INTERVIEWS LARRY HEATON, CEO OF ZOMEDICA CORP.
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-16 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MAY 16, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, IS PLEASED TO ANNOUNCE THE INTERVIEW WITH JUAN COSTELLO, SENIOR ANALYST WITH THE WALL STREET ANALYZER, AND LARRY HEATON, ZOMEDICA'S CHIEF EXECUTIVE OFFICER. YOU CAN VISIT THE WALL STREET ANALYZER (HTTPS://WALLSTREETANALYZER.COM/2022/05/13/ZOMEDICA-CORP-NYSE-AMERICANZOM/) TO LISTEN TO THE FULL INTERVIEW.
|
ZOMEDICA CEO INTERVIEW WITH WALL STREET ANALYZER DISCUSSES FIRST QUARTER 2022 EARNINGS AND FUTURE PLANS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-10 16:25:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MAY 10, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING POINT-OF-CARE DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2022. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS, AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA ANNOUNCES FIRST QUARTER 2022 REVENUES OF $3.8 MILLION; 74% GROSS MARGIN & $192.3 MILLION IN CASH; REVENUE UP 38% FROM 2021 COMBINED REVENUES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-04 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MAY 4, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED ITS SPONSORSHIP WITH THE AMERICAN ASSOCIATION OF FELINE PRACTITIONERS (AAFP). "THE AAFP SUPPORTS FELINE PRACTITIONERS BY PROVIDING TOOLS, GUIDELINES AND RESOURCES TO ASSIST IN DELIVERING CONTINUING, HIGH-QUALITY SERVICE TO THEIR CAT PATIENTS" SAID LARRY HEATON, ZOMEDICA'S CHIEF EXECUTIVE OFFICER, "WE ARE HONORED TO PARTNER WITH SUCH AN ORGANIZATION TO PROVIDE A HEALTHY FUTURE FOR THE FELINE VETERINARY PROFESSION.
|
ZOMEDICA(R) SUPPORTS FELINE ANIMAL HEALTH WITH AMERICAN ASSOCIATION OF FELINE PRACTITIONERS' SPONSORSHIP
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-13 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / APRIL 13, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, IS PLEASED TO ANNOUNCE THAT THE PULSEVET SYSTEM HAS BEEN NAMED THE OFFICIAL SHOCK WAVE THERAPY OF THE AMERICAN QUARTER HORSE ASSOCIATION (AQHA). ZOMEDICA'S PULSEVET SYSTEM IS A WORLD LEADER IN ELECTRO-HYDRAULIC SHOCK WAVE TECHNOLOGY FOR THE TREATMENT OF A WIDE VARIETY OF CONDITIONS IN VETERINARY PATIENTS.
|
ZOMEDICA'S ANNOUNCES DESIGNATION OF PULSEVET SYSTEM AS THE OFFICIAL SHOCK WAVE THERAPY OF THE AMERICAN QUARTER HORSE ASSOCIATION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-04 06:52:00
| null |
ANN ARBOR, MI / ACCESSWIRE / APRIL 4, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THE COMMERCIAL LAUNCH OF ITS NEWEST ASSAY - ENDOGENOUS ACTH (EACTH) - FOR THE TRUFORMA IN-CLINIC BIOSENSOR TESTING PLATFORM. LARRY HEATON, ZOMEDICA'S CHIEF EXECUTIVE OFFICER, COMMENTED, "THE PROPRIETARY TRUFORMA EACTH ASSAY WILL BRING A VALUABLE DIAGNOSTIC TOOL FOR VETERINARIANS INTO THEIR CLINIC FOR THE FIRST TIME.
|
ZOMEDICA ANNOUNCES LAUNCH OF EACTH ASSAY FOR TRUFORMA(R) PLATFORM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-01 16:50:00
| null |
ANN ARBOR, MI / ACCESSWIRE / MARCH 1, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA CORPORATION REPORTS 2021 FOURTH QUARTER & FULL YEAR RESULTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-28 07:30:00
| null |
ANN ARBOR, MICHIGAN--(NEWSFILE CORP. - FEBRUARY 28, 2022) - ZOMEDICA (AMEX: ZOM) TODAY ANNOUNCED THAT LARRY HEATON, CEO WILL BE ATTENDING THE Q1 VIRTUAL INVESTOR SUMMIT. DURING THE PRESENTATION, ZOMEDICA'S CHIEF EXECUTIVE OFFICER, LARRY HEATON, WILL HIGHLIGHT THE COMPANY'S RECENT INTEGRATION OF PULSEVET, INC., IT'S PROGRESS WITH THE TRUFORMA PRODUCT LINE, AND THE RESULTING TRANSFORMATIONAL BUSINESS STRATEGY AND PARTNERSHIPS, AND THE BROADER GOING-FORWARD CORPORATE VISION. THE PRESENTATION WILL BE WEBCAST AND ARCHIVED IN THE...
|
ZOMEDICA ANNOUNCES PARTICIPATION IN THE Q1 VIRTUAL INVESTOR SUMMIT
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-25 16:20:00
| null |
ANN ARBOR, MI / ACCESSWIRE / FEBRUARY 25, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED REVENUES AND GROSS MARGIN FOR THE FOURTH QUARTER AND FULL YEAR 2021. TOTAL REVENUE FOR THE FOURTH QUARTER AND FULL YEAR 2021 WAS $4.1 MILLION, COMPARED TO $0 IN BOTH PERIODS IN 2020.
|
ZOMEDICA ANNOUNCES FOURTH QUARTER AND 2021 REVENUES OF $4.1 MILLION; 73.9% GROSS MARGIN
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-15 06:05:00
| null |
ANN ARBOR, MI / ACCESSWIRE / FEBRUARY 15, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT ADRIAN LOCK, VICE PRESIDENT AND GENERAL MANAGER, WILL LEAD THE COMPANY'S SALES ORGANIZATION, INCLUDING ZOMEDICA FIELD SALES PERSONNEL, SALES MANAGEMENT AND PROFESSIONAL SERVICE VETERINARIANS, AS WELL AS EXISTING PULSEVET SALES PERSONNEL. AS THE FOUNDING CHIEF EXECUTIVE OFFICER OF PULSEVET, MR.
|
ZOMEDICA APPOINTS ADRIAN LOCK TO LEAD SALES ORGANIZATION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-27 06:00:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JANUARY 27, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY PROVIDED AN UPDATE ON ITS MARKETING ACTIVITIES DURING THE FIRST QUARTER OF 2022. PULSEVET SALES & MARKETING INTEGRATION SALES AND MARKETING MANAGEMENT FROM BOTH ZOMEDICA AND PULSEVET COMPLETED PULSEVET SALES TRAINING FOR ZOMEDICA'S 18-STRONG FIELD SALES ORGANIZATION ON THE EVE OF THE 2022 VMX VETERINARY MEETING AND EXPO IN ORLANDO, FLORIDA JANUARY 16-19, 2022.
|
ZOMEDICA PROVIDES UPDATES ON PULSEVET SALES & MARKETING INTEGRATION AND MARKETING ACTIVITIES FOR THE FIRST QUARTER OF 2022
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-10 06:30:00
| null |
ANN ARBOR, MI / ACCESSWIRE / JANUARY 10, 2022 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR THE "COMPANY"), A VETERINARY HEALTH COMPANY OFFERING DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ISSUED THE FOLLOWING LETTER FROM LARRY HEATON, CHIEF EXECUTIVE OFFICER, UPDATING ZOMEDICA'S SHAREHOLDERS REGARDING SEVERAL KEY ACTIVITIES AND EVENTS: DEAR ZOMEDICA SHAREHOLDERS, WITH JUST OVER 60 DAYS IN THE ROLE OF CHIEF EXECUTIVE OFFICER OF ZOMEDICA, I'M WRITING TO SHARE MY PERSPECTIVE ON THE COMPANY, ITS PROGRESS AND OPPORTUNITIES. WHILE WE ARE CURRENTLY CONDUCTING A ROBUST REVIEW OF OUR STRATEGIC PLANS, I THOUGHT YOU MIGHT APPRECIATE SOME CURRENT INSIGHTS NOW.
|
ZOMEDICA CEO PROVIDES UPDATE TO SHAREHOLDERS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-12 16:10:00
| null |
ANN ARBOR, MI / ACCESSWIRE / NOVEMBER 12, 2021 / ZOMEDICA CORP. (NYSE AMERICAN:ZOM) ("ZOMEDICA" OR "COMPANY"), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA ("U.S. GAAP").
|
ZOMEDICA ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-04 06:05:00
| null |
ANN ARBOR, MICH., OCT. 04, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT LARRY HEATON HAS BEEN APPOINTED PRESIDENT EFFECTIVE OCTOBER 1, 2021. MR. HEATON WILL ASSUME THE ROLE OF CHIEF EXECUTIVE OFFICER UPON THE RETIREMENT OF CURRENT CHIEF EXECUTIVE OFFICER ROBERT COHEN ON OCTOBER 31, 2021. FOLLOWING HIS RETIREMENT, MR. COHEN WILL REMAIN ON THE BOARD OF DIRECTORS OF ZOMEDICA.
|
ZOMEDICA APPOINTS LARRY HEATON AS PRESIDENT AND ANNOUNCES CEO SUCCESSION PLAN
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 06:01:00
| null |
ANN ARBOR, MICH., OCT. 01, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THAT IT HAD ACQUIRED THE PULSE VETERINARY TECHNOLOGIES BUSINESSES FOR $70.9 MILLION IN AN ALL-CASH, STOCK TRANSACTION.
|
ZOMEDICA ACQUIRES PULSEVET
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-13 16:17:00
| null |
ANN ARBOR, MICH., SEPT. 13, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, ANNOUNCED THAT SEAN WHELAN HAS BEEN APPOINTED TO ITS BOARD OF DIRECTORS TO FILL THE VACANCY CREATED BY THE RESIGNATION OF CHRISTOPHER WOLFENBERG.
|
SEAN WHELAN APPOINTED TO BOARD OF DIRECTORS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-30 13:20:00
| null |
ANN ARBOR, MICH., JULY 30, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR COMPANION ANIMALS, TODAY ANNOUNCED THE VOTING RESULTS OF ITS 2021 ANNUAL VIRTUAL-ONLY MEETING OF SHAREHOLDERS (THE “MEETING”) HELD ON JULY 30, 2021.
|
ZOMEDICA ANNOUNCES 2021 ANNUAL MEETING RESULTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-06 06:05:00
| null |
FOCUSED ON TRUFORMA ® INSTRUMENT PLACEMENTS AND BUILDING DIRECT SALES ORGANIZATION
|
ZOMEDICA PROVIDES CORPORATE UPDATE
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-17 06:10:00
| null |
FORMER ELANCO ANIMAL HEALTH, JOHNSON & JOHNSON, INTUITIVE SURGICAL, AND ENTEROMEDICS BUSINESS DEVELOPMENT EXECUTIVE JOINS TEAM TO SUPPORT GROWTH OPPORTUNITIES
|
ZOMEDICA HIRES VICE PRESIDENT BUSINESS DEVELOPMENT TO LEAD ACQUISITION AND LICENSING EFFORTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-15 06:01:00
| null |
ANN ARBOR, MICH., APRIL 15, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, ANNOUNCED THAT IT INTENDS TO EXPAND ITS DIRECT SALES ORGANIZATION WHILE PHASING OUT ITS DISTRIBUTOR-BASED SALES EFFORTS.
|
ZOMEDICA TO BUILD DIRECT SALES FORCE FOR TRUFORMA® PLATFORM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-16 06:00:00
| null |
ANN ARBOR, MICH., MARCH 16, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, YESTERDAY RECORDED THE FIRST VETERINARIAN SALE OF TRUFORMA® AND OFFICIALLY ENTERED COMMERCIALIZATION.
|
ZOMEDICA ANNOUNCES FIRST COMMERCIAL SALE OF ITS TRUFORMA® PLATFORM
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-08 06:05:00
| null |
TRUFORMA® PROGRESSING TOWARD COMMERCIALIZATION TRUFORMA® PROGRESSING TOWARD COMMERCIALIZATION
|
ZOMEDICA RETIRES PREFERRED SHARES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-26 16:15:00
| null |
ANN ARBOR, MICH., FEB. 26, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN:ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY REPORTED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020. AMOUNTS, UNLESS SPECIFIED OTHERWISE, ARE EXPRESSED IN U.S. DOLLARS AND PRESENTED UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA (“U.S. GAAP”).
|
ZOMEDICA CORP. ANNOUNCES YEAR END 2020 FINANCIAL RESULTS
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-16 11:37:00
| null |
ANN ARBOR, MICH., FEB. 16, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM), (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT THE UNDERWRITER OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF HAS EXERCISED IN FULL ITS OVER-ALLOTMENT OPTION TO PURCHASE AN ADDITIONAL 13,697,368 COMMON SHARES OF ZOMEDICA AT A PRICE TO THE PUBLIC OF $1.90 PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. AFTER GIVING EFFECT TO THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, THE GROSS PROCEEDS ARE APPROXIMATELY $200.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY ZOMEDICA.
|
ZOMEDICA CORP. ANNOUNCES FULL EXERCISE OF OVER-ALLOTMENT OPTION BY UNDERWRITER
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-11 12:18:00
| null |
ANN ARBOR, MICH., FEB. 11, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM), (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF 91,315,790 COMMON SHARES OF ZOMEDICA, AT A PRICE TO THE PUBLIC OF $1.90 PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. AS PREVIOUSLY ANNOUNCED, ZOMEDICA ALSO HAS GRANTED TO THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO 13,697,368 ADDITIONAL COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.
|
ZOMEDICA CORP. ANNOUNCES CLOSING OF $173.5 MILLION BOUGHT DEAL
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-08 23:00:00
| null |
ANN ARBOR, MICH., FEB. 08, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM), (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT, DUE TO DEMAND, THE UNDERWRITER HAS AGREED TO INCREASE THE SIZE OF THE PREVIOUSLY ANNOUNCED PUBLIC OFFERING AND PURCHASE ON A FIRM COMMITMENT BASIS 91,315,790 COMMON SHARES OF ZOMEDICA, AT A PRICE TO THE PUBLIC OF $1.90 PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT FEBRUARY 11, 2021, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.
|
ZOMEDICA CORP. INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON SHARES TO $173.5 MILLION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-08 17:01:00
| null |
ANN ARBOR, MICH., FEB. 08, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM), (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN UNDERWRITING AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC UNDER WHICH THE UNDERWRITER HAS AGREED TO PURCHASE ON A FIRM COMMITMENT BASIS 13,157,895 COMMON SHARES OF ZOMEDICA, AT A PRICE TO THE PUBLIC OF $1.90 PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT FEBRUARY 11, 2021, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.
|
ZOMEDICA CORP. ANNOUNCES $25.0 MILLION BOUGHT DEAL OFFERING OF COMMON SHARES
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-25 06:10:00
| null |
ANN ARBOR, MICH., JAN. 25, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT IT HAS SIGNED AN AGREEMENT WITH MILLER VETERINARY SUPPLY (“MILLER”) FOR THE DISTRIBUTION OF TRUFORMA™, ZOMEDICA'S FIRST PRODUCT, PLANNED TO BEGIN SALES ON MARCH 30, 2021.
|
ZOMEDICA SIGNS TRUFORMA™ DISTRIBUTION AGREEMENT WITH MILLER VETERINARY SUPPLY
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-18 06:15:00
| null |
ANN ARBOR, MICH., JAN. 18, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ISSUED THE FOLLOWING LETTER FROM ROBERT COHEN, CHIEF EXECUTIVE OFFICER, UPDATING ZOMEDICA'S SHAREHOLDERS REGARDING SEVERAL KEY ACTIVITIES AND EVENTS:
|
ZOMEDICA CEO ISSUES SHAREHOLDER LETTER AS TRUFORMA™ NEARS COMMERCIALIZATION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-04 06:10:00
| null |
ANN ARBOR, MICH., JAN. 04, 2021 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THE APPOINTMENT OF ROBERT COHEN AS CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2021. MR. COHEN PREVIOUSLY SERVED AS THE COMPANY'S INTERIM CEO AND AS A MEMBER OF THE BOARD OF DIRECTORS.
|
ZOMEDICA APPOINTS ROBERT COHEN CEO AS COMPANY NEARS COMMERCIALIZATION OF TRUFORMA™
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-15 08:53:00
| null |
PROGRESS CONTINUING TOWARD COMMERCIALIZATION OF TRUFORMA™ PROGRESS CONTINUING TOWARD COMMERCIALIZATION OF TRUFORMA™
|
ZOMEDICA TO REMAIN DOMICILED IN CANADA
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-07 06:01:00
| null |
ANN ARBOR, MICH., DEC. 07, 2020 (GLOBE NEWSWIRE) -- ZOMEDICA CORP. (NYSE AMERICAN: ZOM) (“ZOMEDICA” OR THE “COMPANY”), A VETERINARY HEALTH COMPANY CREATING POINT-OF-CARE DIAGNOSTICS PRODUCTS FOR DOGS AND CATS, TODAY ANNOUNCED THAT, WITH THE HIRING OF DEBRA ROCK TO LEAD THE COMPANY'S MARKETING DEPARTMENT, ITS INTERNAL COMMERCIAL LEADERSHIP TEAM IS COMPLETE.
|
ZOMEDICA COMPLETES INTERNAL “LAUNCH TEAM” FOR UPCOMING TRUFORMA™ COMMERCIALIZATION
|
ZOM
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.